S ymptomatic patients with aortic stenosis and reduced left ventricular ejection fraction (LVEF) represent a particularly difficult subset of patients to diagnose and to treat. These patients, in fact, pose important diagnostic dilemmas because of the symptoms that may derive primarily from the LV dysfunction, rather than from the stenotic valve, or from the combination of both. According to the current guidelines, 1 severe aortic stenosis is characterized by peak aortic jet velocity >4.0 m/s, mean gradient >40 mm Hg, or when the aortic valve area is <1.0 cm 2 . In the presence of these echocardiographic findings, a symptomatic patient or a patient with reduced LVEF (<50%) is candidate for aortic valve replacement (AVR; class I recommendation). 2, 3 Yet, patients with LV dysfunction often present with an aortic valve area <1.0 cm 2 but with low peak aortic jet velocity (<4.0 m/s). Performance of dobutamine stress echocardiography might help to distinguish those patients with true severe aortic stenosis, who will derive most of the benefit from AVR, from those with moderate aortic stenosis and primary LV dysfunction. In addition, dobutamine stress echocardiography provides strong prognostic information because the lack of contractile reserve is associated with high cardiovascular mortality regardless of treatment. 4, 5 Myocardial fibrosis is among the factors contributing to the lack of contractile reserve and can be detected and quantified by cardiac MRI. When present, myocardial fibrosis is associated with an adverse prognosis. 6, 7 Article see p 604 AVR in patients with LV systolic dysfunction significantly improves, and often normalizes, LVEF, which also translates into improved survival. 8, 9 This occurs despite the fact that LV dysfunction represents one of the factors associated with higher 30-day mortality. Because of these complexities and in the context of frequently associated comorbidities (especially in patients with LV dysfunction), physicians both in Europe and the United States are often reluctant to refer patients with low-flow low-gradient aortic stenosis for surgical AVR, even when fulfilling the criteria for established indications. [10] [11] [12] In this issue of Circulation: Cardiovascular Interventions, Elmariah et al 13 report on the impact of transcatheter AVR (TAVR) and surgical AVR on LV function and related clinical outcomes in patients with LV dysfunction (LVEF <50%) included in the cohort A of the Placement of Aortic Transcatheter Valves (PARTNER) trial. 14 PARTNER A trial randomized 699 patients with aortic stenosis and high risk for surgical AVR (30-day perioperative mortality ≥15%) to undergo either TAVR or surgical AVR. All-cause mortality rates were similar at 1 year (P=0.001 for noninferiority). In the subset of patients from PARTNER with LV dysfunction and complete baseline echocardiographic data, AVR using either surgery or TAVR has been associated with a significant (P<0.0001) and similar improvement in LV function at 1 year, on average +36% after TAVR and +32% after surgical AVR. In addition, no difference in all-cause mortality was observed both at 30 days and at 1 year. Of interest, failure to improve LVEF by 30 days was associated with adverse 1-year outcomes only in patients who underwent TAVR, but not in patients undergoing surgical AVR. These data support invasive treatment, instead of procrastination, and the growing adoption of TAVR now represents an additional opportunity to propose a solution to patients who might otherwise be left untreated.
In addition to these encouraging results, several unknowns remain to be addressed in the future.
First, patients with severely reduced LVEF (ie, <20%) were excluded from the cohort A of the PARTNER trial. It is unknown whether TAVR would portend even greater benefit in this patient subgroup, compared with the known high risk of surgical AVR in this specific subset. Second, the significant interaction between lack of LV function recovery and mortality observed in patients treated with TAVR, but not with surgical AVR, emphasizes the need to search for objective and reliable predictors of LV functional recovery in these patients. In addition to the aforementioned techniques of dobutamine stress echocardiography and MRI, assessing B-type natriuretic peptide levels might play a useful role in further risk stratification of these patients. In fact, elevated B-type natriuretic peptide levels are associated with markedly decreased 1-year survival after surgical AVR, even after adjusting for EuroScore. 15, 16 Third, the interaction between TAVR and functional mitral regurgitation has not been explored fully. LV loading conditions will obviously affect the measurement of systolic ejection. One fourth of the patients with LV dysfunction presented with severe-to-moderate mitral regurgitation. In this study, presence of mitral regurgitation was not associated with significant LV functional improvement at 30 days by univariate analysis. Yet, we do not know whether and to what extent mitral regurgitation improved after TAVR. A recently published multicenter registry showed that mitral insufficiency improved 1 year after TAVR in 47% and 35% of the patients with severe and moderate regurgitation, respectively. 17 One might speculate that the predictive role of severe-to-moderate mitral regurgitation in the present study was hidden by its improvement as it occurs after TAVR. These considerations are challenging the concept that mitral intervention, for example, repair should be performed at the time of the aortic intervention, especially when the mechanism of mitral regurgitation is mainly functional. Fourth, the importance of residual paravalvular leaks in patients with LV dysfunction undergoing TAVR needs further understanding. From the present analysis, we learn that there was no impact of the presence of moderate-to-severe paravalvular leaks on the LV improvement ≤30 days. Yet, patients with LV dysfunction were at greater risk of repeat hospitalization after TAVR, but not after surgical AVR. It is tempting to speculate that the presence of paravalvular leaks in patients treated by TAVR might have exposed them to residual volume overload and more frequent episodes of acute heart failure than seen after surgical AVR. The availability of newer generation valves that result in less frequent occurrence of paravalvular leaks after TAVR will provide an opportunity to test this hypothesis.
In summary, this interesting subanalysis of the PARTNER A trial by Elmariah et al 13 provides important evidence in support of considering TAVR as an additional therapeutic option in patients with low-flow, low-gradient aortic stenosis. This is great news. Yet, not all patients equally enjoyed clinical benefit from this treatment strategy. Understanding who are the best candidates for TAVR and being able to identify those patients with LV dysfunction who will greatly benefit remains the challenge ahead of us. How obvious the latter statement may seem, the challenge remains: caring for this complex patient group poses multiple and interrelated clinical dilemmas that are best addressed on a case by case basis by experienced heart teams. 2
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